InvestorsHub Logo

riskon

03/05/21 10:42 AM

#3355 RE: Ronin #3354

FEND definitely not a huge flop.

https://nextbreath.global/

Targeting to improve air quality for 750,000,000 children worldwide.

riskon

03/05/21 10:43 AM

#3356 RE: Ronin #3354

Pulmazole trial pushed back longer than expected; but is that really the only news on that front? I doubt it.

riskon

03/05/21 10:44 AM

#3357 RE: Ronin #3354

$JNJ & $PULM are dosing patients right now. PUR1800 can be repurposed for cytokine storm Covid-19 treatment.

riskon

03/09/21 11:58 PM

#3376 RE: Ronin #3354

Just in case everyone here missed it. If Sensory Cloud does indeed succeed to the fullest extent in the global launch of the Next Breath Charitable Organization -- and FEND gets into the hands of 750,000,000 schoolchildren around the world.... or anywhere close to such...

That could imply $15.3 Billion EBITDA to Pulmatrix according to the royalty structure. And at a 20x multiple and the current 85M fully diluted shares, translates into $3,600 of shareholder value. The math doesn't lie.

Of course the price per FEND solution or number of refills per year could change and lower numbers above -- but the point is FEND could absolutely epic for Pulmatrix shareholders. All at no cost.

"Farfetched positive implications" ....

https://nextbreath.global/


$PULM